Incyte: latest news - GoINPHARMA
Wednesday, 12 December 2018 - 0:33

Incyte

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

Positive momentum for biotech Incyte

The moment awaited for a long time by many investors of US-based Incyte has apparently come. The Wilmington, Delaware-based biotech company is about to obtain a positive approval by a panel of FDA experts for its rheumatoid arthritis therapy Olumiant…

A detailed profile of biotech Incyte

Financial Times has published a long article about Incyte, the Wilmington, Delaware-based biotech widely believed to be the next big target in the big pharma. Incyte’s main assets are undoubtedly Epacadostat, a second-generation immunotherapy (IDO enzyme inhibitors) for the treatment…

Battle for control of Incyte about to start

The battle for the control of biotechnology group Incyte is reportedly about to start. The three most likely bidders are Gilead Sciences, Bristol-Myers Squibb and Amgen, which could soon place a bid for the rich oncology pipeline that the company…